Article
Immunology
Yaping Chen, Yanhui Xiao, Ying Ye, Feng Jiang, Hanqing He, Linyun Luo, Haiping Chen, Lubin Shi, Qiuyue Mu, Wei Chen, Xue Guo, Min Zhang, Jun Li, Qinghu Guan, Zhiping Chen, Xiaoming Yang
Summary: This study demonstrates that in infants, coadministration of an inactivated enterovirus 71 vaccine (EV71 vaccine) with trivalent split-virion inactivated influenza vaccine (IIV3) is safe and does not interfere with immunogenicity.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Xiu Hui Tan, Wei Lim Chong, Vannajan Sanghiran Lee, Syahril Abdullah, Kartini Jasni, Saiful Qushairi Suarni, David Perera, I-Ching Sam, Yoke Fun Chan
Summary: HFMD is a childhood disease caused by EV-A71 and CV-A16. The capsid loops play a crucial role in the immunogenicity of these viruses. Substituting CV-A16 loops into EV-A71 disrupted its immunogenicity.
Review
Immunology
Mei-Ling Li, Shin-Ru Shih, Blanton S. Tolbert, Gary Brewer
Summary: Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina, with potential neurological complications and death. Vaccination is the most efficient way to control virus infection, with multiple types of vaccines currently in development and use.
Article
Health Care Sciences & Services
Yan Li, Fan Gao, Yamin Wang, Jing Li, Yuxi Zhang, Huakun Lv, Shenyu Wang, Haitao Yang, Xiaoqiang Liu, Keli Li, Huaqing Wang, Zundong Yin, Zhenglun Liang, Zhijie An, Qunying Mao, Zijian Feng
Summary: A study compared the immunogenicity of three EV-A71 vaccines in children aged 6-35 months and found that they were mutually non-inferior in seroconversion rates and had no significant differences in safety, supporting the use of any of these vaccines to prevent EV-A71 associated diseases.
LANCET REGIONAL HEALTH-WESTERN PACIFIC
(2021)
Article
Immunology
Nagisa Tokunoh, Shigeyuki Tamiya, Masato Watanabe, Toru Okamoto, Jessica Anindita, Hiroki Tanaka, Chikako Ono, Toshiro Hirai, Hidetaka Akita, Yoshiharu Matsuura, Yasuo Yoshioka
Summary: The study suggests that a nasal vaccine containing inactivated whole-virion can be highly effective in protection against SARS-CoV-2 infection.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Virology
Zoltan Vajo, Gergely Balaton, Peter Vajo, Peter Torzsa
Summary: The results of the study indicate that using a whole virion vaccine with aluminum phosphate adjuvants can reduce the dose of viral hemagglutinin in pediatric and adolescent patients while maintaining immunogenicity, safety, and tolerability.
Article
Infectious Diseases
Shilei Wang, Zhiqiang Xie, Lili Huang, Xu Zhou, Jian Luo, Yuelian Yang, Changgui Li, Peng Duan, Wenting Xu, Dandan Chen, Bing Wu, Yongli Yang, Xueying Liu, Yanxia Wang, Zhenghong Yuan, Di Qu, Ze Chen, Shengli Xia
Summary: The alum-adjuvanted H7N9 whole-virion inactivated vaccine was found to be safe and highly immunogenic in a population aged >= 12 years in China. After receiving two doses of the 7.5-mg vaccine, 98.2% of participants achieved an HI titre of >= 40, with a geometric mean titre of 192.6.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Medicine, General & Internal
Kunsulu Zakarya, Lespek Kutumbetov, Mukhit Orynbayev, Yergali Abduraimov, Kulyaisan Sultankulova, Markhabat Kassenov, Gulbanu Sarsenbayeva, Ilyas Kulmagambetov, Timur Davlyatshin, Maria Sergeeva, Marina Stukova, Berik Khairullin
Summary: The QazCovid-in (R) vaccine, developed in Kazakhstan, showed good safety and tolerability in phase 1 and 2 clinical trials, inducing significant immune response that lasts at least 6 months.
Article
Immunology
Tsai-Teng Tzeng, Kit Man Chai, I-Hua Chen, Ray-Yuan Chang, Jen-Ron Chiang, Shih-Jen Liu
Summary: The addition of CpG 1018 to alum-adjuvanted influenza vaccines enhances immune responses and provides stronger protection, while also reducing the amount of antigen required.
EMERGING MICROBES & INFECTIONS
(2023)
Article
Multidisciplinary Sciences
Meifen Wang, Tao Chen, Junchao Peng, Yunjiao Luo, Lijiang Du, Zhiying Lu, Jianzhu He, Chunli Liu, Quan Gan, Wei Ma, Zhikuan Cun, Qiongmei Zheng, Weiying Chen, Yonglin Chen, Mei Han, Guojun Liu, Jiwei Li
Summary: This study investigated the temporal and spatial distribution of HFMD and the prevalence of different pathogens in Kunming. CV-A6 and CV-A16 had significant outbreaks in different years, and the epidemiological characteristics varied among different regions. Therefore, research on multivalent combined vaccines and implementation of preventive measures are needed to control the incidence of HFMD-like diseases.
SCIENTIFIC REPORTS
(2022)
Review
Medicine, Research & Experimental
Peter J. Hotez, Maria Elena Bottazzi
Summary: The development of mRNA and adenovirus-vectored vaccines against COVID-19 has impressed the scientific community, but global vaccine equity has not been achieved. Low- and middle-income countries still rely on traditional technology approaches to produce vaccines. Various vaccines, including those based on whole inactivated virus and protein-based platforms, have shown promising results and good safety profiles. There is an urgent need to accelerate vaccine distribution in these countries by the end of 2022.
ANNUAL REVIEW OF MEDICINE
(2022)
Article
Immunology
Ui Yoon Choi, Ki Hwan Kim, Kyung Yil Lee, Jong-Hyun Kim, Chun Soo Kim, Byung Wook Eun, Hwang Min Kim, Dong Ho Kim, Song Eun Song, Dae Sun Jo, Jin Lee, Sang Hyuk Ma, Kwang Nam Kim, Jin Han Kang
Summary: The study evaluated the immunogenicity and safety of a novel quadrivalent inactivated influenza vaccine, GC3110A, in Korean children aged 6-35 months, showing comparable results to the traditional trivalent vaccine TIV in terms of immunogenicity and safety.
Article
Immunology
Natasha Rodrigues de Oliveira, Sergio Jorge, Mara Andrade Colares Maia, Tiffany Thurow Bunde, Ana Carolina Kurz Pedra, Amilton Clair Pinto Seixas Neto, Thais Larre Oliveira, Odir Antonio Dellagostin
Summary: The study compared the efficacy of in-house bacterins produced with standard and virulent strains. Results showed that virulent strains provided better protection, suggesting the importance of maintaining virulent strains in vaccine formulations to enhance immunogenicity and efficacy.
Article
Cell Biology
Yu-Li Lin, Pei-Yun Cheng, Chiao-Li Chin, Kuan-Ting Chuang, Jing-Yi Lin, Ning Chang, Chun-Kei Pan, Cheng-Sheng Lin, Siao-Cian Pan, Bor-Luen Chiang
Summary: This study found that the polysaccharide PS-G from Ganoderma lucidum can be used as a potential adjuvant for developing mucosal bivalent vaccines against EV-A71 and EV-D68. The vaccines induced strong immune responses, producing specific antibodies that neutralized the viruses and provided protection.
JOURNAL OF BIOMEDICAL SCIENCE
(2023)
Article
Pharmacology & Pharmacy
Dayna Cheng, Sheng-Wen Huang, Yi-Hsuan Tsai, Yun-Yin Lien, Jen-Ren Wang
Summary: This study used synthetic biotechnology to generate reverse genetics viruses of different genotypes, and developed an effective vaccine candidate against EV-A71. Using antigenic cartography, we found antigenic differences among different genotypes, and several sera were able to effectively neutralize various EV-A71 genotypes. Based on antigenic mapping and neutralization activities, B4 7008-HF and C4 M79 may be potential vaccine candidates against EV-A71.
ANTIVIRAL RESEARCH
(2023)